Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1177/0962280212465498 http://scihub22266oqcxt.onion/10.1177/0962280212465498 C4843088!4843088!23242385     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Stat+Methods+Med+Res 2016 ; 25 (2): 716-27 Nephropedia Template TP {{tp|p=23242385|t=2016. Some recommendations for multi-arm multi-stage trials |pdf=|usr=}}{{23242385}} gab.com Text Some recommendations for multi-arm multi-stage trials JO: Stat Methods Med Res http://www.kidney.de/pget.php?&tw=1&pmid=23242385 #FOAvip Multi-arm multi-stage designs can improve the efficiency of the drug-development process by evaluating multiple experimental arms against a common control within one trial. This reduces the number of patients required compared to a series of trials testing each experimental arm separately against control. By allowing for multiple stages experimental treatments can be eliminated early from the study if they are unlikely to be significantly better than control. Using the TAILoR trial as a motivating example, we explore a broad range of statistical issues related to multi-arm multi-stage trials including a comparison of different ways to power a multi-arm multi-stage trial; choosing the allocation ratio to the control group compared to other experimental arms; the consequences of adding additional experimental arms during a multi-arm multi-stage trial, and how one might control the type-I error rate when this is necessary; and modifying the stopping boundaries of a multi-arm multi-stage design to account for unknown variance in the treatment outcome. Multi-arm multi-stage trials represent a large financial investment, and so considering their design carefully is important to ensure efficiency and that they have a good chance of succeeding. Twit Text FOAVip Some recommendations for multi-arm multi-stage trials ????Stat Methods Med Res http://www.kidney.de/pget.php?&tw=1&pmid=23242385 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=23242385 #FOAvip English Wikipedia <ref>{{Cite pmid|23242385}}</ref> Some recommendations for multi-arm multi-stage trials #MMPMID23242385 Wason J; Magirr D; Law M; Jaki T Stat Methods Med Res 2016[Apr]; 25 (2): 716-27 PMID23242385show ga Multi-arm multi-stage designs can improve the efficiency of the drug-development process by evaluating multiple experimental arms against a common control within one trial. This reduces the number of patients required compared to a series of trials testing each experimental arm separately against control. By allowing for multiple stages experimental treatments can be eliminated early from the study if they are unlikely to be significantly better than control. Using the TAILoR trial as a motivating example, we explore a broad range of statistical issues related to multi-arm multi-stage trials including a comparison of different ways to power a multi-arm multi-stage trial; choosing the allocation ratio to the control group compared to other experimental arms; the consequences of adding additional experimental arms during a multi-arm multi-stage trial, and how one might control the type-I error rate when this is necessary; and modifying the stopping boundaries of a multi-arm multi-stage design to account for unknown variance in the treatment outcome. Multi-arm multi-stage trials represent a large financial investment, and so considering their design carefully is important to ensure efficiency and that they have a good chance of succeeding. äSome recommendations for multi-arm multi-stage trials (epmc).pdf DeepDyve Pubget Overpricing